Testicular cancer: Maintaining the high cure rate

ONCOLOGY

Volumn 17, Issue 2, 2003, Pages 218-228

  Raghavan, Derek ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADJUVANT THERAPY; CANCER STAGING; DISEASE MANAGEMENT; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; RISK FACTOR; SEMINOMA; TESTIS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; MALE; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 0038819572     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Mostofi FK, Price EB Jr: Tumors of the Male Genital System: Atlas of Tumor Pathology, 2nd series, pp 1-175. Washington, DC, Armed Forces Institute of Pathology, 1979.
2. Raghavan D, Neville AM: The biology of testicular tumours, in Innes-Williams D, Chisholm G (eds): Scientific Foundations of Urology, 2nd ed, pp 785-796. London, William Heinemann Medical Books, 1992.
3. Skakkebaek NE: Carcinoma in situ of the testis: Frequency and relationship to invasive germ cell tumours in infertile men. Histopa- thology 2:157-170, 1978.
4. Horwich A, Hamilton CR, Fisher C: Rare tumours of the testis and paratesticular tissues, in Raghavan D, Brecher M, Johnson D, et al (eds): Textbook of Uncommon Cancer, 2nd ed, pp 95-113. Chichester, NY, Wiley Liss, 1998.
5. Raghavan D, Sullivan AL, Peckham MJ, et al: Elevated serum alphafetoprotein and seminoma: Clinical evidence for a histologic continuum? Cancer 50:982-989, 1982.
6. Atkin NB, Baker MC: i(12p): Specific chromosomal marker in seminoma and malignant teratoma of the testis? Cancer Genet Cylogenet 10:199-204, 1983.
7. Rodriguez E, Mathew S, Reuter V, et al: Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52:2285-2291, 1992.
8. Raghavan D, Zalcberg J, Grygiel JJ, et al: Multiple atypical nevi: A cutaneous marker of germ cell tumors. J Clin Oncol 12:2284-2287, 1994.
9. Rapley EA, Crockford GP, Teare D, et al: Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 24:197-200, 2000.
10. Einhorn LH: Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41:3275-3280, 1981.
11. Peckham MJ, Barrett A, McEhvain TJ, et al: Non-seminoma germ cell tumours (malignant teratoma) of the testis: Results of treatment and an analysis of prognostic factors. Br J Urol 53:162-172, 1981.
12. Strohmeyer T, Reese D, Press M, et al: Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol 153:511-515, 1995.
13. Bokemeyer C, Kuczyk MA, Dunn T: Expression of stem-cell factor and its receptor c-kit proto-oncogene in germ cell tumours. J Pathol 122:301-306, 1996.
14. Boyer MJ, Raghavan D: Extragonadal germ cell tumors, in Peckham MJ, Pinedo H, Veronesi U (eds): Oxford Textbook of Oncology, pp 2169-2189. Oxford, Oxford University Press, 1995.
15. Shivdasani RA, Kantoff PW: Extragonadal germ cell tumors, in Raghavan D, Scher HI, Leibel S, et al (eds): Principles and Practice of Genitourinary Oncology, pp 751- 764. Philadelphia, Lippincott-Raven, 1997.
16. Bokemeyer C, Nichols CR, Droz JP, et al: Extragonadal germ cell tumors of the medi-astinum and retroperitoneum: Results from an international analysis. J Clin Oncol 20:1864- 1873, 2002.
17. Stephen RA: The clinical presentation of testicular tumours. Br J Urol 34:448-450, 1962.
18. Sandeman TF: Symptoms and early management of germinal tumours of the testis. Med J Aust 2:281-284, 1979.
19. Donohue JP, Zachary JM, Maynard BR: Distribution of nodal metastases in nonsemi- nomatous testis cancer. J Urol 128:315-320, 1982.
20. Horwich A, Bajorin D: Testicular cancer: Presentation, assessment, and prognosis, in Raghavan D, Scher HI, Leibel S, et al (eds): Principles andj'ractice of Genitourinary Oncology, pp 671-682. Philadelphia, Lippincott- Raven, 1997.
21. Bosl GJ, Motzer RJ: Testicular germ- cell cancer. N Engl J Med 337:242-253, 1997.
22. Raghavan D, Mackintosh JF, Fox RM, et al: Improved survival after brain metastases in non-seminomatous germ cell tumours with combined modality treatment. Br J Urol 60:364-367, 1987.
23. Bokemeyer C, Nowak P, Haupt A, et al: Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 15:1449-1454, 1997.
24. Horwith A, Bajorin D: Testicular cancer-presentation, assessment and prognosis, in Raghavan D, Scher HI, Leibel SA, et al (eds): Principles and Practice of Genitourinary Oncology, pp'671-682. Philadelphia, Lip- pincott-Raven, 1997.
25. Greene FL, Page DL, Fleming ID, et al (eds): American Joint Committee on Cancer Staging Manual, 6th ed, pp 317-322. New York, Springer, 2002.
26. Hilton S, Schwartz LH: Radiologic imaging of genitourinary neoplasms, in Raghavan D, Scher HI, Leibel SA, et al (eds): Principles and Practice of Genitourinary Oncology, pp 33-42. Philadelphia, Lippincott- Raven, 1997.
27. Stephens AW, Gonin R, Hutchins GD, et al: Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14:1637-1641, 1996.
28. Lange PH, Raghavan D: Clinical applications of tumor markers in testicular cancer, in Donohue JP (ed): Testis Tumors, pp 111- 130. Baltimore, Williams &Wilkins, 1983.
29. Jewett MAS, Lange PH, Raghavan D: Controversies in the treatment of early stage nonseminomatous testicular cancer, in Raghavan D, Scher HI, Leibel S, et al (eds): Principles and Practice of Genitourinary Oncology, pp 703-713. Philadelphia, Lippincott-Raven, 1997.
30. Warde PR, Gospodarowicz MK, Goodman PJ, et al: Results of a policy of surveillance in stage I testicular seminoma. Int J Radial Oncol BiolPhys 27:11-15, 1993.
31. Francis R, Bower M, Brunstrom G, et al: Surveillance for stage I testicular germ cell tumours: Results and cost benefit analysis of management options. Eur J Cancer 36:1925-1932, 2000.
32. Horwich A, Mason M, Hendry W: Testicular tumours, in Souhami RL, Tannock I, Hohenberger P, et al: Oxford Textbook of Oncology, 2nd edition, pp 2002-2035. New York, Oxford University Press, 2002.
33. Raghavan D, Peckham MJ, Heyderman E, et al: Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis. Br J Cancer 45:161-173, 1982.
34. Raghavan D, Vogelzang NJ, Bosl GJ, et al: Tumor classification and size in germ- cell testicular cancer: Influence on the occurrence of metastases. Cancer 5p: 1591-1595, 1982.
35. Rorth M, Jacobsen GK, von der Maase H, et al: Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. J Clin Oncol 9:1543-1548, 1991.
36. Peckham MJ, Barrett A, Husband JE, et al: Orchiectomy alone in testicular stage I non- seminomatous germ-cell tumours. Lancet 2:678-680, 1982.
37. Raghavan D: 'Active surveillance' for stage I testis cancer: Attaining maturity at 21 years. Eur J Cancer 36:1891-1894, 2000.
38. Raghavan D, Colls B, Levi J, et al: Surveillance for stage" I non-seminomatous germ cell tumours of the testis: The optimal protocol has not yet been defined. Br J Urol 61:522- 526, 1988.
39. Sturgeon JF, Jewett MA, Alison RE, et al: Surveillance after orchiectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 10:564-568, 1992.
40. Raghavan D: Follow-up of the patient with testicular cancer, in Johnson FS, Virgo K (eds): Cancer Patient Follow-up. St. Louis, Mosby-Year Book, 1995.
41. Segelov E, Raghavan D, Kronenberg H: Acute leukemia following chemotherapy including etoposide for testicular carcinoma. Aust N Z J Med 23:718-719, 1993.
42. Cullen MH, Stenning SP, Parkinson MC: Short-course adjuvant chemotherapy in high- risk stage I nonseminomatous germ cell tumors of the testis. A Medical Research Council Report. J Clin Oncol 14:1106-1113, 1996.
43. Gospodarowicz MK, Warde PR: Management of stage I-II seminoma, in Raghavan D, Scher HI, Leibel SA, Lange P (eds): Principles and Practice of Genitourinary Oncology, pp 683-696. Philadelphia, Lippincott-Raven, 1997.
44. Foster RS: Surgery of the retroperitoneum, in Raghavan D (ed): American Cancer Society Atlas of Germ Cell Tumors. Toronto, BC Decker, in press.
45. Stoter G, Loehrer PJ Sr, Levi J: Management of stage II and good risk stage III and IV nonse(minomatous germ cell tumors, in Raghavan D, Scher HI, Leibel S, et al (eds): Principles and Practice of Genitourinary Oncology, pp 715-721. Philadelphia, Lippincott-Raven, 1997.
46. Williams SD, Stablein DM, Einhorn LH, et al: Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433-1438, 1987.
47. Bosl GJ, Geller NL, Cirrincione C, et al:Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403-3407, 1983.
48. Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to "good-risk" and "poor-risk" studies. J Clin Oncol 6:786-792, 1986.
49. Birch R, Williams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1988.
50. Levi JA, Thomson D, Sandeman T, et al: A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: Role of maintenance and long- term follow-up. J Clin Oncol 6:1154-1160, 1988.
51. Mead GM, Stenning SP, Parkinson MC, et al: The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 10:85-94, 1992.
52. Levi JA, Thomson D, Sandeman T, et al: A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: Role of maintenance and long- term follow-up. J Clin Oncol 6:1154-1160, 1988.
53. Bosl GJ, Geller NL, Vogelzang NJ, et al: Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 5:436-440, 1987.
54. International Germ Cell Cancer Collaborative Group: International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997.
55. Williams SD, Birch R, Einhom LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987.
56. Levi JA, Raghavan D, Harvey V, et al: The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 11:1300-1305, 1993.
57. Loehrer PJ Sr, Johnson D, Elson P, et al: Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 13:470-476, 1995.
58. deWit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good-prognosis testicular non- seminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 15:1837- 1843, 1997.
59. Bajorin DF, Bosl GJ: Bleomycin in germ cell tumor therapy: Not all regimens are-created equal. J Clin Oncol 15:1717-1719, 1997.
60. Einhom LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989.
61. Horwich A, DIejfer DT, Fossa SD, et al: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A multi- institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15:1844-1852, 1997.
62. Levine EG, Raghavan D: Treatment of refractory testis cancer: Salvage or savage chemotherapy? Eur J Cancer 27:932-936, 1991.
63. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163- 1172, 1991.
64. Margolin K, Doroshow JH, Ahn C, et al: Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous tern-cell support. J Clin Oncol 14:2631-2637, 1996.
65. Margolin K: High-dose chemotherapy and stem-cell support in the treatment of poor- risk germ cell cancer, in Raghavan D (ed): Atlas of Germ Cell Tumors. Toronto, BC Decker, in press.
66. Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etoposide and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996.
67. Motzer RJ, Mazumdar M, Bajorin DF, et al: High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546-2552, 1997.
68. Newlands ES, Begent RH, Rustin GJ, et al: Further advances in the management of malignant teratomas of the testis and other sites. Lancet 1:948-951, 1983.
69. Bower M, Newlands ES, Holden L, et al: Treatment of men with metastatic non-semtnomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 8:477-483, 1997.
70. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994.
71. Bokemeyer C, Gerl A, Schoffski P, et al: Gemcitabine in patients with relapsed or cis-platin-refractory testticular cancer. J Clin Oncol 17:512-516, 1999.
72. Einhorn LH, Stender MJ, Williams SD: Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 17:509-511, 1999.
73. Motzer RJ, Sheinfeld J, Mazumdar M, et al: Paclitaxel, ifosfamide, and cisplatin second- line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18:2413-2418, 2000.
74. Hinton S, Catalano P, Einhorn LH, et al: Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20:1859-1863, 2002.
75. Rick O, Bokemeyer C, Beyer J, et al: Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, eto- poisde, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19:81-88, 2001.
76. BoyerM, Raghavan D: Toxicity of treatment of germ cell tumors. Semin Oncol 19:128-142, 1992.
77. Boyer MJ, Roth BJ: Toxicity of treatment of germ cell tumors, in Raghavan D, Scher HI, Leibel S, et al (eds): Principles and Practice of Genitourinary Oncology, pp 754- 764. Philadelphia, Lippincott-Raven, 1997.
78. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout A, et al: Second cancer risk following testicular cancer: A follow-up study of 1909 patients. J Clin Oncol 11:415-424, 1993.
79. Travis LB, Curtis RE, Storm H, et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89:1429-1439, 1997.
80. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long- term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000.